Mirum Pharmaceuticals price target raised to $65 from $63 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $65 from $63 and keeps an Overweight rating on the shares. Q4 was “uneventful” as pipeline progress remains on track and revenues were recently pre-announced, says the analyst, who also notes that management reiterated 2025 sales guidance of $420M-$435M.